Penalty Amount
$96,500,000
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.
The manufacturers’ settlement funds, totaling approximately $96.5 million, are to be distributed through a claims process to eligible consumers who purchased certain generic drugs. The release does not specify individual consumer award amounts.
This release concerns antitrust settlements, not a privacy enforcement action. In vendor, distribution, and other commercial agreements in the pharmaceutical supply chain, review antitrust compliance representations and covenants, restrictions on sharing competitively sensitive pricing or sales information, and protocols governing communications with competitors. Review employee training and escalation procedures for trade association meetings and other industry contacts; privacy, consent, and breach-notification clauses are not implicated by the facts described here.
Entity
Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure
Industry
Healthcare"Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure"
"totaling approximately $96.5 million"
"claims that those companies illegally conspired to raise the prices of generic drugs."
"This month, the U.S. District Court for the District of Connecticut granted preliminary approval"
"New Jersey and a coalition of 47 other states and territories"
Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.
$96.5M
Oregon and a multistate coalition announced a plan to distribute settlement funds to people who paid inflated prices for certain generic drugs. The release says a federal court granted preliminary approval of the distribution plan this month; it does not give the date of that approval, and the reported conduct concerns alleged antitrust violations rather than a privacy violation.
New Jersey joined a coalition of state attorneys general in filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive conversations it holds, including those involving children and mental health. The states seek safeguards for consumers’ personal information in any sale or transfer of the company’s business or assets; the release does not report a fine or final finding of violations.
A multistate coalition co-led by New Jersey won a federal court order rejecting the Trump Administration’s decision not to request funding for the CFPB. The order struck down that decision and directed the Administration to follow the law and fund the agency; no monetary penalty or privacy violation is described.
New Jersey’s Attorney General and Division of Consumer Affairs alerted the public that three synthetic kratom-related compounds became illegal to possess or sell in the state under a temporary federal scheduling order. The release describes a controlled-substance alert, not a privacy enforcement action, and identifies no company, privacy violation, or monetary penalty.
$2.3M
Laboratory Corporation of America Holdings agreed to pay $2,287,455 to participating states and strengthen its security and vendor-management practices following an investigation into the 2019 breach at its debt-collection vendor, AMCA. The breach potentially exposed information of more than 27.5 million people nationwide, including sensitive information belonging to approximately 10.2 million LabCorp patients.